Abstract:ICH established S7B and E14 guidelines in 2005 to prevent drug-induced torsade de pointes (TdP), effectively preventing the development of high-risk drugs. However, those guidelines unfortunately hampered the development of some potentially valuable drug candidates despite not being proven to be proarrhythmic. In response, Comprehensive In Vitro Proarrhythmia Assay (CiPA) and Exposure-Response Modeling were proposed in 2013 to reinforce proarrhythmic risk assessment. In 2022, ICH released E14/S7B Q&As (Stage 1), emphasizing a "double negative" nonclinical scenario for low-risk compounds. For "non-double negative" compounds, new Q&As are expected to be enacted as Stage 2 shortly, in which more detailed recommendations for proarrhythmia models and proarrhythmic surrogate markers will be provided. This review details the onset mechanisms of drug-induced TdP, including IKr inhibition, pharmacokinetic factors, autonomic regulation and reduced repolarization reserve. It also explores the utility of proarrhythmic surrogate markers (J-Tpeak, Tpeak-Tend and terminal repolarization period) besides QT interval. Finally, it presents various in silico, in vitro, ex vivo and in vivo models for proarrhythmic risk prediction, such as CiPA in silico model, iPS cell-derived cardiomyocyte sheet, Langendorff perfused heart preparation, chronic atrioventricular block animals (dogs, monkeys, pigs and rabbits), acute atrioventricular block rabbits, methoxamine-sensitized rabbits, and genetically engineered rabbits for specific long QT syndromes. Those models along with the surrogate markers can play important roles in quantifying TdP risk of new compounds, impacting late-phase clinical design and regulatory decision-making, and preventing adverse events on post-marketing clinical use. Significance Statement Since ICH S7B/E14 guidelines unfortunately hampered the development of some potentially valuable compounds with unproven proarrhythmic risk, Comprehensive In Vitro Proarrhythmia Assay and Exposure-Response Modeling were proposed in 2013 to reinforce proarrhythmic risk assessment of new compounds. In 2022, ICH released Q&As (Stage 1) emphasizing "double negative" nonclinical scenario for low-risk compounds, and new Q&As (Stage 2) for "non-double negative" compounds are expected. This review delves into proarrhythmic mechanisms with surrogate markers, and explores various models for proarrhythmic risk prediction.

Mechanisms underlying spontaneous termination of Torsade de Pointes in an experimental model of long QT syndrome

Mechanisms underlying arrhythmogenesis in long QT syndrome

Mechanisms of torsades de pointes: an update

Torsade de pointes in a patient with complete atrioventricular block and pacemaker failure, misdiagnosed with epilepsy.

Repolarization dispersion and life-threatening ventricular tachyarrhythmias in patients with congestive heart failure

Repolarization Injury and Occurrence of Torsades de Pointes During Acute Takotsubo Syndrome

Incidence and clinical characteristics of patients with torsades de pointes complicating acquired atrioventricular block

A case of short QT‐interval postventricular arrhythmia arrest from Torsade De Pointes, a new phenotype, or the result of tachycardia‐mediated imbalance

Early Afterdepolarizations in the Familial Long Qtu Syndrome

Prevention of Torsade de Pointes in Hospital Settings

Roles of Atrial Arrhythmias in Triggering Torsade de Pointes in Patients With Acquired Long-QT Syndrome

Mechanisms of Premature Ventricular Complexes Caused by QT Prolongation.

Assessment of corrected JT-peak (JTpc) and Tpeak-to-Tend (TpTec) as proarrhythmia biomarkers in non-human primates: Outcome from a HESI consortium

Drug-induced QT interval prolongation and torsades de pointes

R-From-T as a Common Mechanism of Arrhythmia Initiation in Long QT Syndromes

Drug-induced long QT syndrome: Concept and non-clinical models for predicting the onset of drug-induced torsade de pointes in patients in compliance with ICH E14/S7B guidance

Contribution of cytokine-mediated prolongation of QTc interval to the multi-hit theory of Torsade de Pointes

Mutations In Cytoplasmic Loops Of The Kcnq1 Channel And The Risk Of Life-Threatening Events Implications For Mutation-Specific Response To Beta-Blocker Therapy In Type 1 Long-Qt Syndrome

Optimized J to T peak and T peak to T end measurements in nonclinical species administered moxifloxacin and amiodarone

Key clinical considerations for demonstrating the utility of preclinical models to predict clinical drug-induced torsades de pointes

Spontaneous termination of ventricular tachycardia in the human heart